zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: Van Herk Investments
26 janv. 2024 12h00 HE | Zealand Pharma
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
19 janv. 2024 11h30 HE | Zealand Pharma
Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
17 janv. 2024 10h30 HE | Zealand Pharma
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
zealand_logo_RGB_01.png
Zealand Pharma completes registration of capital increase
12 janv. 2024 05h00 HE | Zealand Pharma
Company announcement – No. 3 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...
zealand_logo_RGB_01.png
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
10 janv. 2024 11h15 HE | Zealand Pharma
Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
zealand_logo_RGB_01.png
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
08 janv. 2024 15h45 HE | Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
02 janv. 2024 02h00 HE | Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
zealand_logo_RGB_01.png
Total number of shares and voting rights in Zealand Pharma at December 29, 2023
29 déc. 2023 11h00 HE | Zealand Pharma
Company announcement – No. 46 / 2023 Total number of shares and voting rights in Zealand Pharma at December 29, 2023 Copenhagen, Denmark, December 29, 2023 – Zealand Pharma A/S (“Zealand”)...
zealand_logo_RGB_01.png
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
23 déc. 2023 04h47 HE | Zealand Pharma
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection...
zealand_logo_RGB_01.png
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
22 déc. 2023 04h30 HE | Zealand Pharma
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S...